The Market Reports

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Selective Cox-2 Inhibitors Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Meloxicam
1.2.3 Celecoxib
1.2.4 Etoricoxib
1.2.5 Imrecoxib
1.2.6 Etodolac
1.2.7 Parecoxib
1.2.8 Others
1.3 Market by Application
1.3.1 Global Selective Cox-2 Inhibitors Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Rheumatoid Arthritis
1.3.3 Osteoarthritis
1.3.4 Spondylosis Chronica Ankylopoietica
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Selective Cox-2 Inhibitors Market Perspective (2019-2030)
2.2 Selective Cox-2 Inhibitors Growth Trends by Region
2.2.1 Global Selective Cox-2 Inhibitors Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Selective Cox-2 Inhibitors Historic Market Size by Region (2019-2024)
2.2.3 Selective Cox-2 Inhibitors Forecasted Market Size by Region (2025-2030)
2.3 Selective Cox-2 Inhibitors Market Dynamics
2.3.1 Selective Cox-2 Inhibitors Industry Trends
2.3.2 Selective Cox-2 Inhibitors Market Drivers
2.3.3 Selective Cox-2 Inhibitors Market Challenges
2.3.4 Selective Cox-2 Inhibitors Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Selective Cox-2 Inhibitors Players by Revenue
3.1.1 Global Top Selective Cox-2 Inhibitors Players by Revenue (2019-2024)
3.1.2 Global Selective Cox-2 Inhibitors Revenue Market Share by Players (2019-2024)
3.2 Global Selective Cox-2 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Selective Cox-2 Inhibitors Revenue
3.4 Global Selective Cox-2 Inhibitors Market Concentration Ratio
3.4.1 Global Selective Cox-2 Inhibitors Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Selective Cox-2 Inhibitors Revenue in 2023
3.5 Selective Cox-2 Inhibitors Key Players Head office and Area Served
3.6 Key Players Selective Cox-2 Inhibitors Product Solution and Service
3.7 Date of Enter into Selective Cox-2 Inhibitors Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Selective Cox-2 Inhibitors Breakdown Data by Type
4.1 Global Selective Cox-2 Inhibitors Historic Market Size by Type (2019-2024)
4.2 Global Selective Cox-2 Inhibitors Forecasted Market Size by Type (2025-2030)
5 Selective Cox-2 Inhibitors Breakdown Data by Application
5.1 Global Selective Cox-2 Inhibitors Historic Market Size by Application (2019-2024)
5.2 Global Selective Cox-2 Inhibitors Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Selective Cox-2 Inhibitors Market Size (2019-2030)
6.2 North America Selective Cox-2 Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Selective Cox-2 Inhibitors Market Size by Country (2019-2024)
6.4 North America Selective Cox-2 Inhibitors Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Selective Cox-2 Inhibitors Market Size (2019-2030)
7.2 Europe Selective Cox-2 Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Selective Cox-2 Inhibitors Market Size by Country (2019-2024)
7.4 Europe Selective Cox-2 Inhibitors Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Selective Cox-2 Inhibitors Market Size (2019-2030)
8.2 Asia-Pacific Selective Cox-2 Inhibitors Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Region (2019-2024)
8.4 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Selective Cox-2 Inhibitors Market Size (2019-2030)
9.2 Latin America Selective Cox-2 Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Selective Cox-2 Inhibitors Market Size by Country (2019-2024)
9.4 Latin America Selective Cox-2 Inhibitors Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Selective Cox-2 Inhibitors Market Size (2019-2030)
10.2 Middle East & Africa Selective Cox-2 Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Country (2019-2024)
10.4 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Boehringer-Ingelheim
11.1.1 Boehringer-Ingelheim Company Detail
11.1.2 Boehringer-Ingelheim Business Overview
11.1.3 Boehringer-Ingelheim Selective Cox-2 Inhibitors Introduction
11.1.4 Boehringer-Ingelheim Revenue in Selective Cox-2 Inhibitors Business (2019-2024)
11.1.5 Boehringer-Ingelheim Recent Development
11.2 TerSera Therapeutics
11.2.1 TerSera Therapeutics Company Detail
11.2.2 TerSera Therapeutics Business Overview
11.2.3 TerSera Therapeutics Selective Cox-2 Inhibitors Introduction
11.2.4 TerSera Therapeutics Revenue in Selective Cox-2 Inhibitors Business (2019-2024)
11.2.5 TerSera Therapeutics Recent Development
11.3 Iroko Pharmaceuticals
11.3.1 Iroko Pharmaceuticals Company Detail
11.3.2 Iroko Pharmaceuticals Business Overview
11.3.3 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Introduction
11.3.4 Iroko Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2019-2024)
11.3.5 Iroko Pharmaceuticals Recent Development
11.4 Apotex
11.4.1 Apotex Company Detail
11.4.2 Apotex Business Overview
11.4.3 Apotex Selective Cox-2 Inhibitors Introduction
11.4.4 Apotex Revenue in Selective Cox-2 Inhibitors Business (2019-2024)
11.4.5 Apotex Recent Development
11.5 Yung Shin Pharmaceutical
11.5.1 Yung Shin Pharmaceutical Company Detail
11.5.2 Yung Shin Pharmaceutical Business Overview
11.5.3 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Introduction
11.5.4 Yung Shin Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2019-2024)
11.5.5 Yung Shin Pharmaceutical Recent Development
11.6 Breckenridge Pharmaceutical
11.6.1 Breckenridge Pharmaceutical Company Detail
11.6.2 Breckenridge Pharmaceutical Business Overview
11.6.3 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Introduction
11.6.4 Breckenridge Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2019-2024)
11.6.5 Breckenridge Pharmaceutical Recent Development
11.7 Meda Pharmaceuticals
11.7.1 Meda Pharmaceuticals Company Detail
11.7.2 Meda Pharmaceuticals Business Overview
11.7.3 Meda Pharmaceuticals Selective Cox-2 Inhibitors Introduction
11.7.4 Meda Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2019-2024)
11.7.5 Meda Pharmaceuticals Recent Development
11.8 Cipla
11.8.1 Cipla Company Detail
11.8.2 Cipla Business Overview
11.8.3 Cipla Selective Cox-2 Inhibitors Introduction
11.8.4 Cipla Revenue in Selective Cox-2 Inhibitors Business (2019-2024)
11.8.5 Cipla Recent Development
11.9 Glenmark Pharmaceuticals
11.9.1 Glenmark Pharmaceuticals Company Detail
11.9.2 Glenmark Pharmaceuticals Business Overview
11.9.3 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Introduction
11.9.4 Glenmark Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2019-2024)
11.9.5 Glenmark Pharmaceuticals Recent Development
11.10 Teva
11.10.1 Teva Company Detail
11.10.2 Teva Business Overview
11.10.3 Teva Selective Cox-2 Inhibitors Introduction
11.10.4 Teva Revenue in Selective Cox-2 Inhibitors Business (2019-2024)
11.10.5 Teva Recent Development
11.11 PuraCap Pharmaceutical
11.11.1 PuraCap Pharmaceutical Company Detail
11.11.2 PuraCap Pharmaceutical Business Overview
11.11.3 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Introduction
11.11.4 PuraCap Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2019-2024)
11.11.5 PuraCap Pharmaceutical Recent Development
11.12 Almirall Limited
11.12.1 Almirall Limited Company Detail
11.12.2 Almirall Limited Business Overview
11.12.3 Almirall Limited Selective Cox-2 Inhibitors Introduction
11.12.4 Almirall Limited Revenue in Selective Cox-2 Inhibitors Business (2019-2024)
11.12.5 Almirall Limited Recent Development
11.13 Lupin Pharmaceuticals
11.13.1 Lupin Pharmaceuticals Company Detail
11.13.2 Lupin Pharmaceuticals Business Overview
11.13.3 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Introduction
11.13.4 Lupin Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2019-2024)
11.13.5 Lupin Pharmaceuticals Recent Development
11.14 Aurobindo Pharma
11.14.1 Aurobindo Pharma Company Detail
11.14.2 Aurobindo Pharma Business Overview
11.14.3 Aurobindo Pharma Selective Cox-2 Inhibitors Introduction
11.14.4 Aurobindo Pharma Revenue in Selective Cox-2 Inhibitors Business (2019-2024)
11.14.5 Aurobindo Pharma Recent Development
11.15 Pfizer
11.15.1 Pfizer Company Detail
11.15.2 Pfizer Business Overview
11.15.3 Pfizer Selective Cox-2 Inhibitors Introduction
11.15.4 Pfizer Revenue in Selective Cox-2 Inhibitors Business (2019-2024)
11.15.5 Pfizer Recent Development
11.16 Mylan
11.16.1 Mylan Company Detail
11.16.2 Mylan Business Overview
11.16.3 Mylan Selective Cox-2 Inhibitors Introduction
11.16.4 Mylan Revenue in Selective Cox-2 Inhibitors Business (2019-2024)
11.16.5 Mylan Recent Development
11.17 Takeda
11.17.1 Takeda Company Detail
11.17.2 Takeda Business Overview
11.17.3 Takeda Selective Cox-2 Inhibitors Introduction
11.17.4 Takeda Revenue in Selective Cox-2 Inhibitors Business (2019-2024)
11.17.5 Takeda Recent Development
11.18 Bayer
11.18.1 Bayer Company Detail
11.18.2 Bayer Business Overview
11.18.3 Bayer Selective Cox-2 Inhibitors Introduction
11.18.4 Bayer Revenue in Selective Cox-2 Inhibitors Business (2019-2024)
11.18.5 Bayer Recent Development
11.19 Novacap
11.19.1 Novacap Company Detail
11.19.2 Novacap Business Overview
11.19.3 Novacap Selective Cox-2 Inhibitors Introduction
11.19.4 Novacap Revenue in Selective Cox-2 Inhibitors Business (2019-2024)
11.19.5 Novacap Recent Development
11.20 Abbott
11.20.1 Abbott Company Detail
11.20.2 Abbott Business Overview
11.20.3 Abbott Selective Cox-2 Inhibitors Introduction
11.20.4 Abbott Revenue in Selective Cox-2 Inhibitors Business (2019-2024)
11.20.5 Abbott Recent Development
11.21 Geri-Care
11.21.1 Geri-Care Company Detail
11.21.2 Geri-Care Business Overview
11.21.3 Geri-Care Selective Cox-2 Inhibitors Introduction
11.21.4 Geri-Care Revenue in Selective Cox-2 Inhibitors Business (2019-2024)
11.21.5 Geri-Care Recent Development
11.22 Perrigo
11.22.1 Perrigo Company Detail
11.22.2 Perrigo Business Overview
11.22.3 Perrigo Selective Cox-2 Inhibitors Introduction
11.22.4 Perrigo Revenue in Selective Cox-2 Inhibitors Business (2019-2024)
11.22.5 Perrigo Recent Development
11.23 Kopran
11.23.1 Kopran Company Detail
11.23.2 Kopran Business Overview
11.23.3 Kopran Selective Cox-2 Inhibitors Introduction
11.23.4 Kopran Revenue in Selective Cox-2 Inhibitors Business (2019-2024)
11.23.5 Kopran Recent Development
11.24 Merck
11.24.1 Merck Company Detail
11.24.2 Merck Business Overview
11.24.3 Merck Selective Cox-2 Inhibitors Introduction
11.24.4 Merck Revenue in Selective Cox-2 Inhibitors Business (2019-2024)
11.24.5 Merck Recent Development
11.25 Hengrui pharmaceutical
11.25.1 Hengrui pharmaceutical Company Detail
11.25.2 Hengrui pharmaceutical Business Overview
11.25.3 Hengrui pharmaceutical Selective Cox-2 Inhibitors Introduction
11.25.4 Hengrui pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2019-2024)
11.25.5 Hengrui pharmaceutical Recent Development
11.26 Kelun Group
11.26.1 Kelun Group Company Detail
11.26.2 Kelun Group Business Overview
11.26.3 Kelun Group Selective Cox-2 Inhibitors Introduction
11.26.4 Kelun Group Revenue in Selective Cox-2 Inhibitors Business (2019-2024)
11.26.5 Kelun Group Recent Development
11.27 Qilu Pharmaceutical
11.27.1 Qilu Pharmaceutical Company Detail
11.27.2 Qilu Pharmaceutical Business Overview
11.27.3 Qilu Pharmaceutical Selective Cox-2 Inhibitors Introduction
11.27.4 Qilu Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2019-2024)
11.27.5 Qilu Pharmaceutical Recent Development
11.28 Taro Pharmaceuticals 
11.28.1 Taro Pharmaceuticals  Company Detail
11.28.2 Taro Pharmaceuticals  Business Overview
11.28.3 Taro Pharmaceuticals  Selective Cox-2 Inhibitors Introduction
11.28.4 Taro Pharmaceuticals  Revenue in Selective Cox-2 Inhibitors Business (2019-2024)
11.28.5 Taro Pharmaceuticals  Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables

List of Tables
Table 1. Global Selective Cox-2 Inhibitors Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Meloxicam
Table 3. Key Players of Celecoxib
Table 4. Key Players of Etoricoxib
Table 5. Key Players of Imrecoxib
Table 6. Key Players of Etodolac
Table 7. Key Players of Parecoxib
Table 8. Key Players of Others
Table 9. Global Selective Cox-2 Inhibitors Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 10. Global Selective Cox-2 Inhibitors Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 11. Global Selective Cox-2 Inhibitors Market Size by Region (2019-2024) & (US$ Million)
Table 12. Global Selective Cox-2 Inhibitors Market Share by Region (2019-2024)
Table 13. Global Selective Cox-2 Inhibitors Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 14. Global Selective Cox-2 Inhibitors Market Share by Region (2025-2030)
Table 15. Selective Cox-2 Inhibitors Market Trends
Table 16. Selective Cox-2 Inhibitors Market Drivers
Table 17. Selective Cox-2 Inhibitors Market Challenges
Table 18. Selective Cox-2 Inhibitors Market Restraints
Table 19. Global Selective Cox-2 Inhibitors Revenue by Players (2019-2024) & (US$ Million)
Table 20. Global Selective Cox-2 Inhibitors Market Share by Players (2019-2024)
Table 21. Global Top Selective Cox-2 Inhibitors Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Selective Cox-2 Inhibitors as of 2023)
Table 22. Ranking of Global Top Selective Cox-2 Inhibitors Companies by Revenue (US$ Million) in 2023
Table 23. Global 5 Largest Players Market Share by Selective Cox-2 Inhibitors Revenue (CR5 and HHI) & (2019-2024)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Selective Cox-2 Inhibitors Product Solution and Service
Table 26. Date of Enter into Selective Cox-2 Inhibitors Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Selective Cox-2 Inhibitors Market Size by Type (2019-2024) & (US$ Million)
Table 29. Global Selective Cox-2 Inhibitors Revenue Market Share by Type (2019-2024)
Table 30. Global Selective Cox-2 Inhibitors Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 31. Global Selective Cox-2 Inhibitors Revenue Market Share by Type (2025-2030)
Table 32. Global Selective Cox-2 Inhibitors Market Size by Application (2019-2024) & (US$ Million)
Table 33. Global Selective Cox-2 Inhibitors Revenue Market Share by Application (2019-2024)
Table 34. Global Selective Cox-2 Inhibitors Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 35. Global Selective Cox-2 Inhibitors Revenue Market Share by Application (2025-2030)
Table 36. North America Selective Cox-2 Inhibitors Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. North America Selective Cox-2 Inhibitors Market Size by Country (2019-2024) & (US$ Million)
Table 38. North America Selective Cox-2 Inhibitors Market Size by Country (2025-2030) & (US$ Million)
Table 39. Europe Selective Cox-2 Inhibitors Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 40. Europe Selective Cox-2 Inhibitors Market Size by Country (2019-2024) & (US$ Million)
Table 41. Europe Selective Cox-2 Inhibitors Market Size by Country (2025-2030) & (US$ Million)
Table 42. Asia-Pacific Selective Cox-2 Inhibitors Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 43. Asia-Pacific Selective Cox-2 Inhibitors Market Size by Region (2019-2024) & (US$ Million)
Table 44. Asia-Pacific Selective Cox-2 Inhibitors Market Size by Region (2025-2030) & (US$ Million)
Table 45. Latin America Selective Cox-2 Inhibitors Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Latin America Selective Cox-2 Inhibitors Market Size by Country (2019-2024) & (US$ Million)
Table 47. Latin America Selective Cox-2 Inhibitors Market Size by Country (2025-2030) & (US$ Million)
Table 48. Middle East & Africa Selective Cox-2 Inhibitors Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 49. Middle East & Africa Selective Cox-2 Inhibitors Market Size by Country (2019-2024) & (US$ Million)
Table 50. Middle East & Africa Selective Cox-2 Inhibitors Market Size by Country (2025-2030) & (US$ Million)
Table 51. Boehringer-Ingelheim Company Detail
Table 52. Boehringer-Ingelheim Business Overview
Table 53. Boehringer-Ingelheim Selective Cox-2 Inhibitors Product
Table 54. Boehringer-Ingelheim Revenue in Selective Cox-2 Inhibitors Business (2019-2024) & (US$ Million)
Table 55. Boehringer-Ingelheim Recent Development
Table 56. TerSera Therapeutics Company Detail
Table 57. TerSera Therapeutics Business Overview
Table 58. TerSera Therapeutics Selective Cox-2 Inhibitors Product
Table 59. TerSera Therapeutics Revenue in Selective Cox-2 Inhibitors Business (2019-2024) & (US$ Million)
Table 60. TerSera Therapeutics Recent Development
Table 61. Iroko Pharmaceuticals Company Detail
Table 62. Iroko Pharmaceuticals Business Overview
Table 63. Iroko Pharmaceuticals Selective Cox-2 Inhibitors Product
Table 64. Iroko Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2019-2024) & (US$ Million)
Table 65. Iroko Pharmaceuticals Recent Development
Table 66. Apotex Company Detail
Table 67. Apotex Business Overview
Table 68. Apotex Selective Cox-2 Inhibitors Product
Table 69. Apotex Revenue in Selective Cox-2 Inhibitors Business (2019-2024) & (US$ Million)
Table 70. Apotex Recent Development
Table 71. Yung Shin Pharmaceutical Company Detail
Table 72. Yung Shin Pharmaceutical Business Overview
Table 73. Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Product
Table 74. Yung Shin Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2019-2024) & (US$ Million)
Table 75. Yung Shin Pharmaceutical Recent Development
Table 76. Breckenridge Pharmaceutical Company Detail
Table 77. Breckenridge Pharmaceutical Business Overview
Table 78. Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Product
Table 79. Breckenridge Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2019-2024) & (US$ Million)
Table 80. Breckenridge Pharmaceutical Recent Development
Table 81. Meda Pharmaceuticals Company Detail
Table 82. Meda Pharmaceuticals Business Overview
Table 83. Meda Pharmaceuticals Selective Cox-2 Inhibitors Product
Table 84. Meda Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2019-2024) & (US$ Million)
Table 85. Meda Pharmaceuticals Recent Development
Table 86. Cipla Company Detail
Table 87. Cipla Business Overview
Table 88. Cipla Selective Cox-2 Inhibitors Product
Table 89. Cipla Revenue in Selective Cox-2 Inhibitors Business (2019-2024) & (US$ Million)
Table 90. Cipla Recent Development
Table 91. Glenmark Pharmaceuticals Company Detail
Table 92. Glenmark Pharmaceuticals Business Overview
Table 93. Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Product
Table 94. Glenmark Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2019-2024) & (US$ Million)
Table 95. Glenmark Pharmaceuticals Recent Development
Table 96. Teva Company Detail
Table 97. Teva Business Overview
Table 98. Teva Selective Cox-2 Inhibitors Product
Table 99. Teva Revenue in Selective Cox-2 Inhibitors Business (2019-2024) & (US$ Million)
Table 100. Teva Recent Development
Table 101. PuraCap Pharmaceutical Company Detail
Table 102. PuraCap Pharmaceutical Business Overview
Table 103. PuraCap Pharmaceutical Selective Cox-2 Inhibitors Product
Table 104. PuraCap Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2019-2024) & (US$ Million)
Table 105. PuraCap Pharmaceutical Recent Development
Table 106. Almirall Limited Company Detail
Table 107. Almirall Limited Business Overview
Table 108. Almirall Limited Selective Cox-2 Inhibitors Product
Table 109. Almirall Limited Revenue in Selective Cox-2 Inhibitors Business (2019-2024) & (US$ Million)
Table 110. Almirall Limited Recent Development
Table 111. Lupin Pharmaceuticals Company Detail
Table 112. Lupin Pharmaceuticals Business Overview
Table 113. Lupin Pharmaceuticals Selective Cox-2 Inhibitors Product
Table 114. Lupin Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2019-2024) & (US$ Million)
Table 115. Lupin Pharmaceuticals Recent Development
Table 116. Aurobindo Pharma Company Detail
Table 117. Aurobindo Pharma Business Overview
Table 118. Aurobindo Pharma Selective Cox-2 Inhibitors Product
Table 119. Aurobindo Pharma Revenue in Selective Cox-2 Inhibitors Business (2019-2024) & (US$ Million)
Table 120. Aurobindo Pharma Recent Development
Table 121. Pfizer Company Detail
Table 122. Pfizer Business Overview
Table 123. Pfizer Selective Cox-2 Inhibitors Product
Table 124. Pfizer Revenue in Selective Cox-2 Inhibitors Business (2019-2024) & (US$ Million)
Table 125. Pfizer Recent Development
Table 126. Mylan Company Detail
Table 127. Mylan Business Overview
Table 128. Mylan Selective Cox-2 Inhibitors Product
Table 129. Mylan Revenue in Selective Cox-2 Inhibitors Business (2019-2024) & (US$ Million)
Table 130. Mylan Recent Development
Table 131. Takeda Company Detail
Table 132. Takeda Business Overview
Table 133. Takeda Selective Cox-2 Inhibitors Product
Table 134. Takeda Revenue in Selective Cox-2 Inhibitors Business (2019-2024) & (US$ Million)
Table 135. Takeda Recent Development
Table 136. Bayer Company Detail
Table 137. Bayer Business Overview
Table 138. Bayer Selective Cox-2 Inhibitors Product
Table 139. Bayer Revenue in Selective Cox-2 Inhibitors Business (2019-2024) & (US$ Million)
Table 140. Bayer Recent Development
Table 141. Novacap Company Detail
Table 142. Novacap Business Overview
Table 143. Novacap Selective Cox-2 Inhibitors Product
Table 144. Novacap Revenue in Selective Cox-2 Inhibitors Business (2019-2024) & (US$ Million)
Table 145. Novacap Recent Development
Table 146. Abbott Company Detail
Table 147. Abbott Business Overview
Table 148. Abbott Selective Cox-2 Inhibitors Product
Table 149. Abbott Revenue in Selective Cox-2 Inhibitors Business (2019-2024) & (US$ Million)
Table 150. Abbott Recent Development
Table 151. Geri-Care Company Detail
Table 152. Geri-Care Business Overview
Table 153. Geri-Care Selective Cox-2 Inhibitors Product
Table 154. Geri-Care Revenue in Selective Cox-2 Inhibitors Business (2019-2024) & (US$ Million)
Table 155. Geri-Care Recent Development
Table 156. Perrigo Company Detail
Table 157. Perrigo Business Overview
Table 158. Perrigo Selective Cox-2 Inhibitors Product
Table 159. Perrigo Revenue in Selective Cox-2 Inhibitors Business (2019-2024) & (US$ Million)
Table 160. Perrigo Recent Development
Table 161. Kopran Company Detail
Table 162. Kopran Business Overview
Table 163. Kopran Selective Cox-2 Inhibitors Product
Table 164. Kopran Revenue in Selective Cox-2 Inhibitors Business (2019-2024) & (US$ Million)
Table 165. Kopran Recent Development
Table 166. Merck Company Detail
Table 167. Merck Business Overview
Table 168. Merck Selective Cox-2 Inhibitors Product
Table 169. Merck Revenue in Selective Cox-2 Inhibitors Business (2019-2024) & (US$ Million)
Table 170. Merck Recent Development
Table 171. Hengrui pharmaceutical Company Detail
Table 172. Hengrui pharmaceutical Business Overview
Table 173. Hengrui pharmaceutical Selective Cox-2 Inhibitors Product
Table 174. Hengrui pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2019-2024) & (US$ Million)
Table 175. Hengrui pharmaceutical Recent Development
Table 176. Kelun Group Company Detail
Table 177. Kelun Group Business Overview
Table 178. Kelun Group Selective Cox-2 Inhibitors Product
Table 179. Kelun Group Revenue in Selective Cox-2 Inhibitors Business (2019-2024) & (US$ Million)
Table 180. Kelun Group Recent Development
Table 181. Qilu Pharmaceutical Company Detail
Table 182. Qilu Pharmaceutical Business Overview
Table 183. Qilu Pharmaceutical Selective Cox-2 Inhibitors Product
Table 184. Qilu Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2019-2024) & (US$ Million)
Table 185. Qilu Pharmaceutical Recent Development
Table 186. Taro Pharmaceuticals  Company Detail
Table 187. Taro Pharmaceuticals  Business Overview
Table 188. Taro Pharmaceuticals  Selective Cox-2 Inhibitors Product
Table 189. Taro Pharmaceuticals  Revenue in Selective Cox-2 Inhibitors Business (2019-2024) & (US$ Million)
Table 190. Taro Pharmaceuticals  Recent Development
Table 191. Research Programs/Design for This Report
Table 192. Key Data Information from Secondary Sources
Table 193. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Selective Cox-2 Inhibitors Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Selective Cox-2 Inhibitors Market Share by Type: 2023 VS 2030
Figure 3. Meloxicam Features
Figure 4. Celecoxib Features
Figure 5. Etoricoxib Features
Figure 6. Imrecoxib Features
Figure 7. Etodolac Features
Figure 8. Parecoxib Features
Figure 9. Others Features
Figure 10. Global Selective Cox-2 Inhibitors Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 11. Global Selective Cox-2 Inhibitors Market Share by Application: 2023 VS 2030
Figure 12. Rheumatoid Arthritis Case Studies
Figure 13. Osteoarthritis Case Studies
Figure 14. Spondylosis Chronica Ankylopoietica Case Studies
Figure 15. Others Case Studies
Figure 16. Selective Cox-2 Inhibitors Report Years Considered
Figure 17. Global Selective Cox-2 Inhibitors Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 18. Global Selective Cox-2 Inhibitors Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 19. Global Selective Cox-2 Inhibitors Market Share by Region: 2023 VS 2030
Figure 20. Global Selective Cox-2 Inhibitors Market Share by Players in 2023
Figure 21. Global Top Selective Cox-2 Inhibitors Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Selective Cox-2 Inhibitors as of 2023)
Figure 22. The Top 10 and 5 Players Market Share by Selective Cox-2 Inhibitors Revenue in 2023
Figure 23. North America Selective Cox-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. North America Selective Cox-2 Inhibitors Market Share by Country (2019-2030)
Figure 25. United States Selective Cox-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Canada Selective Cox-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Europe Selective Cox-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Europe Selective Cox-2 Inhibitors Market Share by Country (2019-2030)
Figure 29. Germany Selective Cox-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. France Selective Cox-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. U.K. Selective Cox-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Italy Selective Cox-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Russia Selective Cox-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Nordic Countries Selective Cox-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Asia-Pacific Selective Cox-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Asia-Pacific Selective Cox-2 Inhibitors Market Share by Region (2019-2030)
Figure 37. China Selective Cox-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Japan Selective Cox-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. South Korea Selective Cox-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Southeast Asia Selective Cox-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. India Selective Cox-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Australia Selective Cox-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Latin America Selective Cox-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Latin America Selective Cox-2 Inhibitors Market Share by Country (2019-2030)
Figure 45. Mexico Selective Cox-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Brazil Selective Cox-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Selective Cox-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Selective Cox-2 Inhibitors Market Share by Country (2019-2030)
Figure 49. Turkey Selective Cox-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Saudi Arabia Selective Cox-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 51. Boehringer-Ingelheim Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2019-2024)
Figure 52. TerSera Therapeutics Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2019-2024)
Figure 53. Iroko Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2019-2024)
Figure 54. Apotex Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2019-2024)
Figure 55. Yung Shin Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2019-2024)
Figure 56. Breckenridge Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2019-2024)
Figure 57. Meda Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2019-2024)
Figure 58. Cipla Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2019-2024)
Figure 59. Glenmark Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2019-2024)
Figure 60. Teva Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2019-2024)
Figure 61. PuraCap Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2019-2024)
Figure 62. Almirall Limited Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2019-2024)
Figure 63. Lupin Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2019-2024)
Figure 64. Aurobindo Pharma Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2019-2024)
Figure 65. Pfizer Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2019-2024)
Figure 66. Mylan Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2019-2024)
Figure 67. Takeda Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2019-2024)
Figure 68. Bayer Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2019-2024)
Figure 69. Novacap Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2019-2024)
Figure 70. Abbott Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2019-2024)
Figure 71. Geri-Care Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2019-2024)
Figure 72. Perrigo Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2019-2024)
Figure 73. Kopran Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2019-2024)
Figure 74. Merck Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2019-2024)
Figure 75. Hengrui pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2019-2024)
Figure 76. Kelun Group Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2019-2024)
Figure 77. Qilu Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2019-2024)
Figure 78. Taro Pharmaceuticals  Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2019-2024)
Figure 79. Bottom-up and Top-down Approaches for This Report
Figure 80. Data Triangulation
Figure 81. Key Executives Interviewed